SCHEMBL8445805

SCHEMBL8445805

Cc1ccc(S(=O)(=O)OCC2(COC(=O)c3ccccc3)CC2COC(=O)c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.45
ATM Q13315 1/20 0.45
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.41
GAA P10253 2/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.40
RECQL P46063 2/20 0.40
GRK2 P25098 1/20 0.39
STAT3 P40763 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA5 P30532 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
TP53 P04637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8447511 1.00 FOLH1 (0.45) FOLH1ATMMAPTNPC1RAB9A
SCHEMBL14938949 1.00 FOLH1 (0.45) FOLH1ATMMAPTNPC1RAB9A
SCHEMBL9836356 0.93 FOLH1 (0.44) FOLH1ATMMAPTNPC1RAB9A
SCHEMBL9258914 0.82 STAT3 (0.38) ATMMAPTPOLBGAAKMT2A
SCHEMBL9838376 0.79 CYP1A2 (0.42) ATMNPC1RAB9AGAAKMT2A
SCHEMBL8448905 0.78 CES2 (0.46) ATMNPC1KMT2ATSHRCHRNB2
SCHEMBL8447584 0.78 CES2 (0.46) ATMNPC1KMT2ATSHRCHRNB2
SCHEMBL10580678 0.78 FOLH1 (0.49) FOLH1MAPTNPC1RAB9APOLB
SCHEMBL23957738 0.76 RECQL (0.45) FOLH1MAPTNPC1RAB9APOLB
SCHEMBL14938947 0.76 ATM (0.37) FOLH1ATMMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020712-B1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES ARATANA THERAPEUTICS NV (BE) 2018-07-04 EP disclosed
EP-3020712-A1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES Aratana Therapeutics NV (BE) 2016-05-18 EP disclosed
EP-2776414-B1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES ARATANA THERAPEUTICS NV (BE) 2016-03-16 EP disclosed
US-9040699-B2 Method for preparing cyclopropane derivatives ARATANA THERAPEUTICS NV (BE) 2015-05-26 US disclosed
US-20150051394-A1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES ARATANA THERAPEUTICS NV (BE) 2015-02-19 US disclosed
EP-2776414-A1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES Aratana Therapeutics NV (BE) 2014-09-17 EP disclosed
WO-2013068042-A1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES OKAPI SCIENCES NV (BE) 2013-05-16 WO disclosed
EP-0502690-B1 Cyclopropane derivative AJINOMOTO KK (JP) 1999-12-01 EP disclosed
US-5449840-A Viricides AJINOMOTO CO., INC. (JP) 1995-09-12 US disclosed
US-5342840-A Viricides AJINOMOTO CO., INC. (JP) 1994-08-30 US disclosed
EP-0502690-A2 Cyclopropane derivative Ajinomoto Co., Inc. (JP) 1992-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051394-A1 METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES HTR6, P2RY6, HTR1D FOLH1 1392/4885ATM 4621/4885MAPT 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.